New Science and Precision Medicine are closely linked. New Science is a dynamic combination of the best in science and health technology that is projected to drive 61 percent of biopharma revenues until 2026, representing 81% of anticipated industry revenue growth. Precision Medicine has grown with the mapping of the genome to drive the development of personalized treatments for individuals or patient populations. Both work in combination with new, analytical scientific and technological advances to positively impact the biopharma business and help deliver better health outcomes. Discoveries are being made and tested in the cloud. Artificial intelligence and machine learning algorithms are digesting data lakes and helping drive new discoveries, speed development and provide smarter care. Accelerated development in cell and gene therapies (CGT) is causing a fundamental shift in the traditional biopharmaceutical business model. Both represent a medical revolution.
Precision medicine for better patient outcomes
Our cell and gene expertise
Working with clients in all three commercially approved CGT therapies.
Active clients in CGT globally.
We are helping clients across three areas: R&D, supply chain and patient engagement.
Together through data collaboratives
The potential of precision medicine
For the most expensive precision medicine today.1
New cancer drugs are currently in late-stage development, and over 90% of these are targeted therapies.2
Increase in the number of active agents in the global immuno-oncology pipeline.3
What we do
What we think
Voices of Life Sciences
Dr. André T. Dahinden
Managing Director – Life Sciences, Precision Oncology and PHC, Global